# Hot Search #
# Hot Search #
Focused on the market in Hematology/oncology Area
Maintain Targeted Market Share in Stem Cell Transplant Field
Commercialize Domestic Developed CD19 Directed CAR-T
Build R&D Production Facility
Dr. He has served as chairman to the board of directors and CEO of CASI since 2019, as executive chairman from February 2018, and as chairman from February 2012.
Prior to CASI, Dr. He was chairman and CEO of OriGene. He also is the founder and general partner of Emerging Technology Partners, LLC, a life sciences focused venture fund established in 2000. Dr. He has been involved in founding or funding over 100 biotech companies throughout his career, some of which went on to be acquired by significantly larger firms. In the earlier part of his career, Dr. He was one of the first few scientists at Human Genome Sciences, and prior to that, was a research fellow at Massachusetts General Hospital and Mayo Clinic.
Dr. He is an author to more than 25 research publications and inventor of over 30 issued patents. Dr. He received his Ph.D. from Baylor College of Medicine and MBA from The Wharton School of University of Pennsylvania.
Mr. Zhang joined CASI in September 2018 as President of CASI (Beijing) Pharmaceuticals Co., Ltd., which is a subsidiary of CASI, and became Global President of CASI in September 2019.
Mr. Zhang has more than 20 years of management experience in the healthcare and biopharmaceutical industries in the U.S., Asia Pacific, and China. Prior to joining CASI, Mr. Zhang was Vice President, Head of Public Affairs and Corporate Responsibility at Novartis Group (China), focusing on the public affairs/public relations strategy, including initiating Novartis' China policy focusing on NMPA new drug approval reform, intellectual property protection, generic quality consistency evaluation and new regulations on biosimilars. From 2011 to 2016, he was Chief Executive Officer of Sandoz Pharmaceutical (China), a Novartis Company. Mr. Zhang has also held executive leadership roles with Bayer Healthcare and Baxter International Corporation in the U.S. and Asia Pacific.
He holds bachelor and master degrees in nuclear physics from University of Science & Technology of China, an MBA in marketing/finance from the University of California at Los Angeles (UCLA), and received Ph.D. training in political science from University of Utah.
Dr. Zukiwski joined CASI in April 2017 as Global Chief Medical Officer.
Prior to joining CASI, Dr. Zukiwski was Chief Executive Officer and Chief Medical Officer of Arno Therapeutics, responsible for leading the clinical development and regulatory affairs teams to support the company's pipeline. Prior to Arno, Dr. Zukiwski served as Chief Medical Officer and Executive Vice President of Clinical Research at MedImmune. Prior to MedImmune, Dr. Zukiwski held several roles of increasing responsibility at Johnson & Johnson’s (J&J,) . Before joining J&J, he served in clinical oncology positions at pharmaceutical companies such as Hoffmann-LaRoche, Glaxo Wellcome and Rhone- Poulenc Rorer.
Dr. Zukiwski has more than 20 years of experience in global drug development and supported the clinical evaluation and registration of many successful oncology therapeutic agents, including Taxotere®, Xeloda®, Procrit®/Eprex®, Velcade®, Yondelis®, and Doxil®.
Dr. Zukiwski holds a bachelor's degree in pharmacy from the University of Alberta and a Doctor of Medicine degree from the University of Calgary. He conducted his post-graduate training at St. Thomas Hospital Medical Center in Akron, Ohio and the University of Texas MD Anderson Cancer Center.
Dr. Goldschmidt joined CASI in April 2016 as Senior Vice President of Business Development. Currently he serves as Chief Business Development Officer.
Before joining CASI, he held senior positions at several biopharmaceutical companies such as Johnson & Johnson, Wyeth/Pfizer, and GSK. Dr. Goldschmidt brings more than 25 years of commercial and business development experience in the biotechnology and pharmaceutical sectors and had direct leadership responsibilities for the development, launch and brand marketing of numerous products including Velcade®, Yondelis®, Mylotarg®, Torisel®, Hycamtin®, and Doxil®.
Dr. Goldschmidt is a graduate of Villanova University and went on to receive a master’s degree from Drexel University and Ph.D. from Temple University School of Medicine.
Mr. Zhang has been Chief Commercial Officer of CASI since July 2021. Prior to his current position, he was the general manager of CASI, Sales & Marketing, since 2018.
Mr. Zhang has more than 20 years of sales & marketing management experience. Prior to CASI, Mr. Zhang served at Roche Pharmaceuticals for 19 years, with his last role as national operation director. Mr. Zhang also held commercial management positions such as sales and business manager at Mundipharma and Janssen.
Mr. Zhang holds a bachelors degree in pharmacology from Hebei Medical University and holds an EMBA degree from Renmin University of China.
Ms. Wang has been Chief Operation Officer of CASI since 2018.
Ms. Wang has more than 20 years of experience in operation management in international companys. Prior to joining CASI, Ms. Wang was once the vice president of Vcanbio and Marsh & McLennan Companies, responsible for business reorganization, as well as establishment and optimization of the operational system. Ms. Wang has also held executive leadership roles with Schneider Electric SA and Tyco Healthcare.
Ms. Wang holds a bachelor's degree in Metallurgy from China Northeastern University, and master's degree in economics from Renmin University of China.
Ms. Qian has been CASI's Global Controller and vice president since January 2022.
Ms. Qian has more than 17 years of experience in global financial operations and financial management of US and Hong Kong listed companies. Prior to joining CASI, she once served as financial director in Guazi.com, and as chief accounting officer at Wanda Sports Group and completed its initial public offering in Nasdaq. She also had worked in international finance department at Weichai Group and as a senior audit manager at PricewaterhouseCoopers Zhong Tian LLP, Beijing office and PricewaterhouseCoopers, Singapore office.
Ms. Qian received a bachelor's degree in Management from University of International Business and Economics. She is a Certified Public Accountant in the State of New Hampshire and a member of American Institute of Certified Public Accountants. Ms. Qian also qualifies as a Certified Public Accountant in China and a Chartered Professional Accountant in Canada.
Ms. Gao has been serving as CASI's General Counsel since January 2023. Prior to her current position, Ms. Gao was legal director since December 2020.
Ms. Gao has more than 15 years of experience in legal affairs and has served as legal counsultant of several well-known foreign enterprises including Medtronic Beijing, Syngenta Beijing, and Caterpillar. Earlier in her career, Ms. Gao worked as a litigation lawyer specializing international business dispute resolution in Commerce & Finance Law Offices.
Ms. Gao received her bachelor's degree in Economic Law from Jilin University and LL.M. degree in International Business Law from the University of Manchester.